tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising Outlook for Upstream Bio, Inc. Driven by Verekitug’s Clinical Advancements
PremiumRatingsPromising Outlook for Upstream Bio, Inc. Driven by Verekitug’s Clinical Advancements
2M ago
Upstream Bio initiated with an Outperform at Evercore ISI
Premium
The Fly
Upstream Bio initiated with an Outperform at Evercore ISI
2M ago
Upstream Bio, Inc.’s Verekitug: A Promising Buy with Blockbuster Potential in Asthma and COPD Markets
Premium
Ratings
Upstream Bio, Inc.’s Verekitug: A Promising Buy with Blockbuster Potential in Asthma and COPD Markets
2M ago
Upstream Bio files automatic mixed securities shelf
PremiumThe FlyUpstream Bio files automatic mixed securities shelf
3M ago
Upstream Bio reports Q3 revenue $683k, consensus $516.8k
Premium
The Fly
Upstream Bio reports Q3 revenue $683k, consensus $516.8k
3M ago
Upstream Bio’s Promising Trials and Strategic Outlook Drive Buy Rating
Premium
Ratings
Upstream Bio’s Promising Trials and Strategic Outlook Drive Buy Rating
3M ago
Upstream Bio’s verekitug shows prevention of TSLP binding in respiratory disease
PremiumThe FlyUpstream Bio’s verekitug shows prevention of TSLP binding in respiratory disease
4M ago
Positive Phase 2 Results for Upstream Bio’s Verekitug Boost Stock Potential
Premium
Ratings
Positive Phase 2 Results for Upstream Bio’s Verekitug Boost Stock Potential
5M ago
Positive Buy Rating for Upstream Bio, Inc. Driven by Promising Clinical Trial Results for Verekitug
Premium
Ratings
Positive Buy Rating for Upstream Bio, Inc. Driven by Promising Clinical Trial Results for Verekitug
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100